Longitudinal evaluation of hepatic osteodystrophy in children and adolescents with chronic cholestatic liver disease

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 11, 2010, Pages 1127-1134

  Taveira, A T A ^a   Pereira, F A ^a   Fernandes, M I M ^a   Sawamura, R ^a   Nogueira Barbosa, M H ^a   Paula, F J A ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bone mineral density; Bone remodeling; Hepatic osteodystrophy; Insulin like growth factor i; Osteoporosis

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; DEOXYPYRIDINOLINE; MAGNESIUM; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; SOMATOMEDIN C;

ADOLESCENT; ARTICLE; BONE DENSITY; BONE REMODELING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; INTRAHEPATIC CHOLESTASIS; LIVER DISEASE; LIVER OSTEODYSTROPHY; LONGITUDINAL STUDY; MALE; OSTEODYSTROPHY; SCHOOL CHILD;

EID: 78649469088     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500118     Document Type: Article

References (39)

1. Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 1995; 108: 276-283.
2. Gasser RW. Cholestasis and metabolic bone disease - a clinical review. Wien Med Wochenschr 2008; 158: 553-557.
3. Sylvester FA. An update on bone abnormalities associated with gastrointestinal and liver disease. Endocrinologist 2001; 11: 77-85.
4. Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003; 125: 941-966.
5. Janes CH, Dickson ER, Okazaki R, Bonde S, McDonagh AF, Riggs BL. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice. J Clin Invest 1995; 95: 2581-2586.
6. Argao EA, Specker BL, Heubi JE. Bone mineral content in infants and children with chronic cholestatic liver disease. Pediatrics 1993; 91: 1151-1154.
7. Ormarsdottir S, Ljunggren O, Mallmin H, Michaelsson K, Loof L. Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol 2002; 14: 43-48.
8. de Albuquerque Taveira AT, Fernandes MI, Galvao LC, Sawamura R, de Mello V, de Paula FJ. Impairment of bone mass development in children with chronic cholestatic liver disease. Clin Endocrinol 2007; 66: 518-523.
9. Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, et al. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 2002; 87: 4273-4279.
10. Blair JM, Zheng Y, Dunstan CR. RANK ligand. Int J Biochem Cell Biol 2007; 39: 1077-1081.
11. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14: 518-527.
12. Sherlock S, Dooley J. Hepatic transplantation. In: Sherlock S, Dooley J (Editors), Diseases of the liver and biliary system. 11th edn. Malden: Blackwell Science; 2002. p 657-679.
13. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992; 7: 137-145.
14. Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, et al. Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 2008; 11: 6-21.
15. JD. Using SAS PROC MIXED to fit multilevel models, hierarchical models, and individual growth models. J Educ Behav Stat 1998; 24: 323-355.
16. Norris SA, Nelson D. Ethnic differences in bone acquisition. In: Rosen CJ (Editor), Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington: American Society for Bone and Mineral Research; 2008. p 820-827.
17. Henwood MJ, Binkovitz L. Update on pediatric bone health. J Am Osteopath Assoc 2009; 109: 5-12.
18. Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46: 1271-1278.
19. van der Merwe SW, van den Bogaerde JB, Goosen C, Maree FF, Milner RJ, Schnitzler CM, et al. Hepatic osteodystrophy in rats results mainly from portasystemic shunting. Gut 2003; 52: 580-585.
20. Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S, et al. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J Hepatol 2005; 42: 573-577.
21. Newton J, Francis R, Prince M, James O, Bassendine M, Rawlings D, et al. Osteoporosis in primary biliary cirrhosis revisited. Gut 2001; 49: 282-287.
22. Pereira FA, Facincani I, Jorgetti V, Ramalho LN, Volpon JB, Dos Reis LM, et al. Etiopathogenesis of hepatic osteodystrophy in Wistar rats with cholestatic liver disease. Calcif Tissue Int 2009; 85: 75-83.
23. Long RG, Meinhard E, Skinner RK, Varghese Z, Wills MR, Sherlock S. Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease. Gut 1978; 19: 85-90.
24. Compston JE, Thompson RP. Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis. Lancet 1977; 1: 721-724.
25. Reed JS, Meredith SC, Nemchausky BA, Rosenberg IH, Boyer JL. Bone disease in primary biliary cirrhosis: reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology 1980; 78: 512-517.
26. Crosbie OM, Freaney R, McKenna MJ, Hegarty JE. Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. Calcif Tissue Int 1999; 64: 295-300.
27. Duarte MP, Farias ML, Coelho HS, Mendonca LM, Stabnov LM, do Carmo M, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001; 16: 1022-1027.
28. Segre GV, D'Amour P, Hultman A, Potts JT Jr. Effects of hepatectomy, nephrectomy, and nephrectomy/uremia on the metabolism of parathyroid hormone in the rat. J Clin Invest 1981; 67: 439-448.
29. Martin K, Hruska K, Greenwalt A, Klahr S, Slatopolsky E. Selective uptake of intact parathyroid hormone by the liver: differences between hepatic and renal uptake. J Clin Invest 1976; 58: 781-788.
30. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115: 3318-3325.
31. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 2008; 473: 139-146.
32. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999; 140: 4367-4370.
33. Grigorie D, Neacsu E, Marinescu M, Popa O. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. Rom J Intern Med 2003; 41: 409-415.
34. Jorgensen HL, Kusk P, Madsen B, Fenger M, Lauritzen JB. Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab 2004; 22: 132-138.
35. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004; 291: 1108-1113.
36. Vega D, Maalouf NM, Sakhaee K. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/ RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 2007; 92: 4514-4521.
37. Yakar S, Rosen CJ. From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med 2003; 228: 245-252.
38. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110: 771-781.
39. de Paula FJ, Gois-Junior MB, Aguiar-Oliveira MH, Pereira FA, Oliveira CR, Pereira RM, et al. Consequences of lifetime isolated growth hormone (GH) deficiency and effects of short-term GH treatment on bone in adults with a mutation in the GHRH-receptor gene. Clin Endocrinol 2009; 70: 35-40.